The safety and tolerability of an HIV-1 DNA prime–protein boost vaccine (DP6-001) in healthy adult volunteers
| Autor: | Ranajit Pal, Melissa A. O'Neill, Janice P. Adams, Shan Lu, Renita Johnson-Leva, Jaclyn K. Longtine, Mary Dawn T. Co, Phillip D. Markham, Sharone Green, Qiao Yu, Shixia Wang, Jeffrey S. Kennedy, Alan L. Rothman, Karen J. Longtine |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Vasculitis medicine.medical_treatment Immunization Secondary Biology Article Immune system Adjuvants Immunologic Vaccines DNA medicine Humans Hypersensitivity Delayed Adverse effect Skin AIDS Vaccines General Veterinary General Immunology and Microbiology Public Health Environmental and Occupational Health Saponins medicine.disease biology.organism_classification Virology QS21 Vaccination Human Experimentation Infectious Diseases Tolerability Vaccines Subunit Immunology Lentivirus Molecular Medicine Female Adjuvant |
| Zdroj: | Vaccine. 26:4420-4424 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2008.05.090 |
| Popis: | This report describes the safety observations following administration of a polyvalent DNA prime–protein boost HIV-1 vaccine formulated with adjuvant QS21. Local injection site reactions were the most common (65% of subjects), and included type IV delayed-type hypersensitivity (DTH) reactions at prior DNA inoculation sites in 12 of 28 (43%) subjects following protein vaccination. Systemic reactions revealed two cases of vasculitis temporally related to inoculation with recombinant Env protein + QS21 adjuvant. Questions remain regarding the cause of the vasculitis, but the unique DTH observation may have contributed to the high level of immune responses previously reported for this vaccine. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect